Physician profile
Simon E Roselaar
NPI 1689626632
$2,028.82
in general payments reported to CMS, 2019-2025
28 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $535 · 2023: $339 · 2024: $472 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $466.02 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $357.09 | 2022-2025 | |
| Amgen INC. | $168.84 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $129.69 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.50 | 2021-2024 | Jardiance |
| Cleerly, INC. | $75.39 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Astrazeneca Pharmaceuticals Lp | $71.82 | 2021-2025 | Farxiga |
| Cvrx, INC. | $65.78 | 2022 | |
| Daiichi Sankyo INC. | $62.08 | 2024 | Injectafer |
| Heartflow, INC. | $59.31 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $58.93 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $51.78 | 2022 | |
| Astellas Pharma US INC | $49.95 | 2021 | |
| Novo Nordisk INC | $49.19 | 2023-2025 | Wegovy, Ozempic |
| Edwards Lifesciences Corporation | $34.78 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33.21 | 2024-2025 | Eliquis |
| Abbott Laboratories | $29.21 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $19.42 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.68 | 2025 | Lifevest |
| Genzyme Corporation | $18.26 | 2025 | |
| Atricure, INC. | $16.51 | 2025 | Atriclip Laa Exclusion System |
| Bayer Healthcare Pharmaceuticals INC. | $14.88 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.37 | 2022 | |
| G Medical Diagnostic Services, INC. | $13.94 | 2022 | |
| Amarin Pharma, INC. | $13.77 | 2021 | |
| Boston Scientific Corporation | $13.14 | 2023 | Watchman Access System |
| Chiesi USA, INC. | $12.31 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $9.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Roselaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.